View Item 

Show simple item record

In vivo effects of μ‐opioid receptor agonist/δ‐opioid receptor antagonist peptidomimetics following acute and repeated administration
dc.contributor.authorAnand, Jessica P
dc.contributor.authorKochan, Kelsey E
dc.contributor.authorNastase, Anthony F
dc.contributor.authorMontgomery, Deanna
dc.contributor.authorGriggs, Nicholas W
dc.contributor.authorTraynor, John R
dc.contributor.authorMosberg, Henry I
dc.contributor.authorJutkiewicz, Emily M
dc.date.accessioned2018-06-11T17:59:48Z
dc.date.available2019-08-01T19:53:23Zen
dc.date.issued2018-06
dc.identifier.citationAnand, Jessica P; Kochan, Kelsey E; Nastase, Anthony F; Montgomery, Deanna; Griggs, Nicholas W; Traynor, John R; Mosberg, Henry I; Jutkiewicz, Emily M (2018). "In vivo effects of μ‐opioid receptor agonist/δ‐opioid receptor antagonist peptidomimetics following acute and repeated administration." British Journal of Pharmacology 175(11): 2013-2027.
dc.identifier.issn0007-1188
dc.identifier.issn1476-5381
dc.identifier.urihttps://hdl.handle.net/2027.42/144260
dc.publisherWiley Periodicals, Inc.
dc.publisherNational Academies Press
dc.titleIn vivo effects of μ‐opioid receptor agonist/δ‐opioid receptor antagonist peptidomimetics following acute and repeated administration
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelPharmacy and Pharmacology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/144260/1/bph14148.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/144260/2/bph14148_am.pdf
dc.identifier.doi10.1111/bph.14148
dc.identifier.sourceBritish Journal of Pharmacology
dc.identifier.citedreferencePert CB, Pasternak G, Snyder SH ( 1973 ). Opiate agonists and antagonists discriminated by receptor binding in brain. Science 182: 1359 – 1361.
dc.identifier.citedreferenceLee KO, Akil H, Woods JH, Traynor JR ( 1999 ). Differential binding properties of oripavines at cloned μ‐ and δ‐opioid receptors. Eur J Pharmacol 378: 323 – 330.
dc.identifier.citedreferenceLee YS, Kulkarani V, Cowell SM, Ma SW, Davis P, Hanlon KE et al. ( 2011 ). Development of potent μ and δ opioid agonsits with high lipophilicity. J Med Chem 54: 382 – 386.
dc.identifier.citedreferenceLenard NR, Daniels DJ, Portoghese PS, Roerig SC ( 2007 ). Absence of conditioned place preference or reinstatement with bivalent ligands containing μ‐opioid receptor agonist and δ‐opioid receptor antagonist pharmacophores. Eur J Pharmacol 566: 75 – 82.
dc.identifier.citedreferenceMcGrath JC, Lilley E ( 2015 ). Implementing guidelines on reporting research using animals (ARRIVE etc.): new requirements for publication in BJP. Br J Pharmacol 172: 3189 – 3193.
dc.identifier.citedreferenceMosberg HI, Yeomans L, Harland AA, Bender AM, Sobczyk‐Kojiro K, Anand JP et al. ( 2013 ). Opioid peptidomimetics: leads for the design of bioavailable mixed efficacy μ opioid receptor (MOR) agonist/δ opioid receptor (DOR) antagonist ligands. J Med Chem 56: 2139 – 2149.
dc.identifier.citedreferenceNaidu PS, Lichtman AH, Archer CC, May EL, Harris LS, Aceto MD ( 2007 ). NIH 11082 produces antidepressant‐like activity in the mouse tail suspension test through a δ opioid receptor mechanism of action. Eur J Pharmacol 566: 132 – 136.
dc.identifier.citedreferenceBenyamin R, Trescot AM, Datta S, BeunaventurA R, Adlaka R, Sehgal N et al. ( 2008 ). Opioid complications and side effects. Pain Physicaian 11: S 105 –S 120.
dc.identifier.citedreferencePurington LC, Pohozheva ID, Traynor JR, Mosberg HI ( 2009 ). Pentapeptides displaying μ opioid receptor agonist and δ opioid receptor partial agonist/antagonist properties. J Med Chem 52: 7724 – 7731.
dc.identifier.citedreferencePurington LC, Sobczyk‐Kojiro K, Pogozheva ID, Traynor JR, Mosberg HI ( 2011 ). Development and in vitro characterization of a novel bifunctional μ‐agonist/δ‐antagonist opioid tetrapeptide. ACS Chem Biol 6: 1375 – 1381.
dc.identifier.citedreferenceQuock RM, Burkey TH, Varga E, Hosohata Y, Hosohata K, Cowell SM et al. ( 1999 ). The δ opioid receptor: molecular pharmacology, signal transduction, and the determination of drug efficacy. Pharmacol Rev 51: 503 – 532.
dc.identifier.citedreferenceRaehal KM, Bohn LM ( 2011 ). The role of β‐arrestin2 in the severity of antinociceptive tolerance and physical dependence induced by different opioid pain therapeutics. Neuropharmacology 60: 58 – 65.
dc.identifier.citedreferenceRaehal KM, Schmid CL, Groer CE, Bohn LM ( 2011 ). Functional selectivity at the μ‐opioid receptor: implications for understanding opioid analgesia and tolerance. Pharmacol Rev 63: 1001 – 1019.
dc.identifier.citedreferenceRoss S, Peselow E ( 2009 ). The neurobiology of addicitive disorders. Clin Neuropharmacol 32: 269 – 276.
dc.identifier.citedreferenceSalvadori S, Guerrini R, Balboni G, Bianchi C, Bryant SD, Cooper PS et al. ( 1999 ). Further studies on the Dmt–Tic pharmacophore: hydrophobic substituents at the C‐terminus endow δ antagonists to manifest μ agonism or μ antagonism. J Med Chem 42: 5010 – 5019.
dc.identifier.citedreferenceSchiller PW ( 2009 ). Bi‐ or multifunctional opioid peptide drugs. Life Sci 86: 598 – 603.
dc.identifier.citedreferenceSchiller PW, Fundytus ME, Merovitz L, Weltrowska G, Nguten TM‐D, Lemieux C et al. ( 1999 ). The opioid μ agonist/δ antagonist DIPP‐NH2(psi) produces a potent analgesic effect, no physical dependence and less tolerance than morphine in rats. J Med Chem 42: 3520 – 3526.
dc.identifier.citedreferenceSchmidt R, Vogel D, Mrestani‐Klaus C, Brandt W, Neubert K, Chung NN et al. ( 1994 ). Cyclic β‐casomorphin analgoues with mixed μ agonist/δ antagonist properties: synthesis, pharmacological characterization and conformational aspects. J Med Chem 37: 1136 – 1144.
dc.identifier.citedreferenceSelley DE, Cao CC, Liu Q, Childers SR ( 2000 ). Effects of sodium on agonist efficacy for G‐protein activation in μ‐opioid receptor‐transfected CHO cells and rat thalamus. Br J Pharmacol 130: 987 – 996.
dc.identifier.citedreferenceSimon EJ, Groth J ( 1975 ). Kinetics of opiate receptor inactivation by sulfhydryl reagents: evidence for conformational change in presence of sodium ions. Proc Natl Acad Sci U S A 72: 2404 – 2407.
dc.identifier.citedreferenceVáradi A, Marrone GF, Palmer TC, Narayan A, Szabó MR, Le Rouzic V et al. ( 2016 ). Mitragynine/corynantheidine pseudoindoxyls as opioid analgesics with μ agonism and δ antagonism, which do not recruit β‐arrestin‐2. J Med Chem 59: 8381 – 8397.
dc.identifier.citedreferenceZhu Y, King MA, Schuller AGP, Nitsche JF, Reidl M, Elde RP et al. ( 1999 ). Retention of supraspinal δ‐like analgesia and loss of morphine tolerance in δ opioid receptor knockout mice. Neuron 24: 243 – 252.
dc.identifier.citedreferenceAbdelhamid EE, Sultana M, Portoghese PS, Takemori AE ( 1991 ). Selective blockage of the δ opioid receptors prevents the development of morphine tolerance and dependence in mice. J Pharmacol Exp Ther 258: 299 – 303.
dc.identifier.citedreferenceAceto MD, Harris LS, Negus SS, Banks ML, Hughes LD, Akgun E et al. ( 2012 ). MDAN‐21: a bivalent opioid ligand containing μ‐agonist and δ‐antagonist pharmacophores and its effects in rhesus monkeys. International Journal of Medicinal Chemistry 2012: 327257.
dc.identifier.citedreferenceAlexander SPH, Christopoulos A, Davenport AP, Kelly E, Marrion NV, Peters JA et al. ( 2017 ). The Concise Guide to PHARMACOLOGY 2017/18: G protein‐coupled receptors. Br J Pharmacol 174: S17 – S129.
dc.identifier.citedreferenceAltarifi AA, David B, Muchhala KH, Blough BE, Akbarali H, Negus SS ( 2017 ). Effects of acute and repeated treatment with the biased μ opioid receptor agonist TRV130 (oliceridine) on measures of antinociception, gastrointestinal function, and abuse liability in rodents. J Psychopharmacol 31: 730 – 739.
dc.identifier.citedreferenceAnand JP, Boyer BT, Mosberg HI, Jutkiewicz EM ( 2016 ). The behavioral effects of a mixed efficacy antinociceptive peptide, VRP26, following chronic administration in mice. Psychopharmacology (Berl) 233: 2479 – 2487.
dc.identifier.citedreferenceAnand JP, Purington LC, Pogozheva ID, Traynor JR, Mosberg HI ( 2012 ). Modulation of opioid receptor ligand affinity and efficacy using active and inactive state receptor models. Chem Biol Drug Des 80: 763 – 770.
dc.identifier.citedreferenceAnathan S, Kezar HS, Carter RL, Saini SK, Rice KC, Wells JL et al. ( 1999 ). Synthesis, opioid receptor binding, and biological activities of naltrexone‐derived pyrido‐ and pyrimidomorphans. J Med Chem 42: 3527 – 3538.
dc.identifier.citedreferenceAnathan S, Khare NK, Saini SK, Seitz LE, Bartlett JL, Davis P et al. ( 2004 ). Identification of opioid ligands possessing mixed μ agonist/δ antagonist activity among pyridomorphans derived from naloxone, oxymorphone, and hydromorphone. J Med Chem 47: 1400 – 1412.
dc.identifier.citedreferenceBailey CP, Connor M ( 2005 ). Opioids: cellular mechanisms of tolerance and physical dependence. Curr Opin Pharmacol 5: 60 – 68.
dc.identifier.citedreferenceBalboni G, Guerrini R, Salvadori S, Bianchi C, Rizzi D, Bryant SD et al. ( 2002a ). Evaluation of the Dmt–Tic pharmacophore: conversion of a potent δ‐opioid receptor antagonist into a potent δ agonist and ligands with mixed properties. J Med Chem 45: 713 – 720.
dc.identifier.citedreferenceBalboni G, Salvadori S, Guerrini R, Negri L, Giannini E, Jinsmaa Y et al. ( 2002b ). Potent δ‐opioid receptor agonists containing the Dmt–Tic pharmacophore. J Med Chem 45: 5556 – 5563.
dc.identifier.citedreferenceBallantyne JC, LaForge KS ( 2007 ). Opioid dependence and addiction during opioid treatment of chronic pain. Pain 129: 235 – 255.
dc.identifier.citedreferenceBender AM, Griggs NW, Anand JP, Traynor JR, Jutkiewicz EM, Mosberg HI ( 2015 ). Asymmetric synthesis and in vitro and in vivo activity of tetrahydroquinolines featuring a diverse set of polar substitutions at the 6 position as mixed‐efficacy μ opioid receptor/δ opioid receptor ligands. ACS Chem Neurosci 6: 1428 – 1435.
dc.identifier.citedreferenceCai J, Song B, Cai Y, Ma Y, Lam A‐L, Magiera J et al. ( 2014 ). Endomorphin analogues with mixed μ‐opioid (MOP) receptor agonism/δ‐opioid (DOP) receptor antagonism and lacking β‐arrestin2 recruitment activity. Bioorg Med Chem 22: 2208 – 2219.
dc.identifier.citedreferenceCouncil NR ( 2011 ). Guide for the Care and Use of Laboratroy Animals. National Academies Press: Washington DC.
dc.identifier.citedreferenceCurtis MJ, Bond RA, Spina D, Ahluwalia A, Alexander SP, Giembycz MA et al. ( 2015 ). Experimental design and analysis and their reporting: new guidance for publication in BJP. Br J Pharmacol 172: 3461 – 3471.
dc.identifier.citedreferenceDaniels DJ, Lenard NR, Etienne CL, Law PY, Roerig SC, Portoghese PS ( 2005 ). Opioid‐induced tolerance and dependence in mice is modulated by the distance between pharmacophores in a bivalent ligand series. Proc Natl Acad Sci U S A 102: 19208 – 19213.
dc.identifier.citedreferenceFaul F, Erdfelder E, Lang AG, Buchner A ( 2007 ). G * Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods 39: 175 – 191.
dc.identifier.citedreferenceFundytus ME, Schiller PW, Shapiro M, Weltrowska H, Coderre TJ ( 1995 ). Attenuation of morphine tolerance and dependence with the highly selective δ opioid receptor antagonist TIPP(psi). Eur J Pharmacol 286: 105 – 108.
dc.identifier.citedreferenceHarding SD, Sharman JL, Faccenda E, Southan C, Pawson AJ, Ireland S et al. ( 2018 ). The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY. Nucl Acids Res. 46: D1091 – D1106.
dc.identifier.citedreferenceHarland AA, Yeomans L, Griggs NW, Anand JP, Pogozheva ID, Jutkiewicz EM et al. ( 2015 ). Further optimization and evaluation of bioavailable, mixed‐efficacy μ‐opioid receptor (MOR) agonists/δ‐opioid receptor (DOR) antagonists: balancing MOR and DOR affinities. J Med Chem 58: 8952 – 8969.
dc.identifier.citedreferenceHealy JR, Bezawada P, Shim J, Jones JW, Kane MA, MacKerell AD Jr et al. ( 2013 ). Synthesis, modeling, and pharmacological evaluation of UMB 425, a mixed μ agonist/δ antagonist opioid analgesic with reduced tolerance liabilities. ACS Chem Nerosci 4: 1256 – 1266.
dc.identifier.citedreferenceHepburn MJ, Little PJ, Gringas J, Khun CM ( 1997 ). Differential effects of naltrindole on morphine‐induced tolerance and physical dependence in rats. J Pharmacol Exp Ther 281: 1350 – 1356.
dc.identifier.citedreferenceHoran PJ, Mattia A, Bilsky EJ, Weber S, Davis TP, Yamamura HI et al. ( 1993 ). Antinociceptive profile of biphalin, a dimeric enkephalin analog. J Phamacol Exp Ther 265: 1446 – 1454.
dc.identifier.citedreferenceHusbands SM, Neilan CL, Broadbear J, Grundt P, Breeden S, Aceto MD et al. ( 2005 ). BU74, a complex oripavine derivative with potent κ opioid receptor agonism and delayed opioid antagonism. European Journal of Pharmacology 509: 117 – 135.
dc.identifier.citedreferenceJohnston LD, O’malley PM, Bachman JG, Schulenberg JE ( 2009 ). Monitoring the future: national survey results on drug use. Natl Inst Drug Abuse 1: 1 – 721.
dc.identifier.citedreferenceJutkiewicz EM, Brooks EA, Kynaston AD, Rice KC, Woods JH ( 2011 ). Patterns of nicotinic receptor antagonism: nicotine discrimination studies. J Pharmacol Exp Ther 339: 194 – 202.
dc.identifier.citedreferenceKelly E ( 2013 ). Efficacy and ligand bias at the μ‐opioid receptor. Br J Pharmacol 169: 1430 – 1446.
dc.identifier.citedreferenceKilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG ( 2010 ). Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160: 1577 – 1579.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
bph14148.pdf
Size:
712.0KB
Format:
PDF
View/Open
Name:
bph14148_am.pdf
Size:
1.637MB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.